MMWR Surveill Summ. 2022 Jan 21;71(2):1-21. doi: 10.15585/mmwr.ss7102a1.
PROBLEM/CONDITION: Each year, approximately 500,000 immigrants and tens of thousands of refugees (range: 12,000-85,000 during 2001-2020) move to the United States. While still abroad, immigrants, refugees, and others who apply for admission to live permanently in the United States must undergo a medical examination. This examination identifies persons with class A or B conditions. Applicants with class A conditions are inadmissible. Infectious conditions that cause an applicant to be inadmissible include infectious tuberculosis (TB) disease (class A TB), infectious syphilis, gonorrhea, and infectious Hansen's disease. Applicants with class B conditions are admissible but might require treatment or follow-up. Class B TB includes persons who completed successful treatment overseas for TB disease (class B0), those with signs or symptoms suggestive of TB but whose overseas laboratory tests and clinical examinations ruled out current infectious TB disease (class B1), those with a diagnosis of latent TB infection (LTBI) (class B2), and the close contacts of persons known to have TB disease (class B3). Voluntary public health interventions might also be offered during the overseas examination. After arriving in the United States, a follow-up TB examination is recommended for persons with class B TB.
This report summarizes health information that was reported to CDC's Electronic Disease Notification (EDN) system for refugees, immigrants, and eligible others who arrived in the United States during 2014-2019. Eligible others are persons who although not classified as refugees (e.g., certain parolees, special immigrant visa holders, and follow-to-join asylees) are eligible for the same services and benefits as refugees.
The EDN system has both surveillance and programmatic components. The surveillance component is a centralized database that collects 1) health-related data from the overseas medical examination for immigrants with class A or B conditions and for all refugees and eligible others and 2) TB-related data from the postarrival TB examination. The programmatic component is a reporting system that sends arrival notifications to state and local health agencies in the jurisdiction where newly arriving persons have reported intending to live and provides state and local health agencies and other authorized users with medical data from overseas examinations.
During 2014-2019, approximately 3.5 million persons moved to the United States from abroad, including 3.2 million immigrants, 313,890 refugees, and 95,993 eligible others. Among these, the overseas examination identified 139,683 persons (3,903 per 100,000 persons examined) with class B TB, 54 with primary or secondary syphilis (30 per 100,000 persons tested), 761 with latent syphilis (415 per 100,000 persons tested), and, after laboratory testing for gonorrhea was added in 2016, a total of 131 with gonorrhea (374 per 100,000 persons tested). Refugees were offered additional, voluntary interventions, including vaccinations and presumptive treatment for parasites. By 2019, first- and second-dose coverage with measles-containing vaccine were 96% and 80%, respectively. In refugee populations for whom presumptive treatment is recommended, up to 96% of refugees, depending on the specific regimen, were offered and accepted treatment. For the 139,683 persons identified overseas with class B TB, EDN sent arrival notifications and overseas medical data to the appropriate state or local health agency to facilitate postarrival TB examinations. Among 101,119 persons identified overseas as having class B0 TB (6,586) or class B1 TB (94,533), a total of 67,432 (67%) had a complete postarrival examination reported to EDN. Among 35,814 children aged 2-14 years identified overseas with class B2 TB, 20,758 (58%) had a complete postarrival examination reported to EDN. (Adults are not routinely tested for immune reactivity to Mycobacterium tuberculosis during the overseas medical examination.) Among those with a complete postarrival examination reported to EDN, the number with a diagnosis of culture-positive TB disease within the first year of arrival was 464 (688 cases per 100,000 persons examined) for those with class B0 or B1 TB and was 11 (53 cases per 100,000 persons examined) for children with class B2 TB.
During 2014-2019, the overseas medical examination system prevented importation of 6,586 cases of infectious TB, 815 cases of syphilis, and 131 cases of gonorrhea. When the examination is used to offer public health interventions, most refugees (up to 96%) accept the intervention. Postarrival follow-up examinations, which were completed for 88,190 persons and identified 475 cases of culture-positive TB, represent an important opportunity to further limit spread of TB disease in the United States by identifying and providing, if needed, preventive care for those with LTBI or treatment for those with disease.
Federal, state, and local health departments and agencies should continue to use EDN data to monitor, evaluate, and improve health-related programs and policies aimed at U.S.-bound or recently arrived immigrants, refugees, and eligible others. Additional public health interventions that could be offered during the overseas medical examination should be considered (e.g., treatment for LTBI). Finally, for persons with class B TB, measures should be taken to identify and remove barriers to completing postarrival examinations to reduce risk for TB disease and community transmission, along with measures to encourage reporting of completed examinations for better data-driven decision-making.
问题/情况:每年,大约有 50 万移民和数万难民(2001-2020 年期间为 12000-85000 人)移居美国。在国外时,移民、难民和其他申请在美国永久居住的人必须接受体检。该检查确定具有 A 类或 B 类情况的人员。具有 A 类情况的申请人不予受理。导致申请人不合格的传染病包括传染性肺结核(TB)病(A 类 TB)、传染性梅毒、淋病和传染性汉森病。具有 B 类情况的申请人可入境,但可能需要治疗或随访。B 类 TB 包括在海外成功完成结核病治疗的人员(B0 类)、那些具有 TB 症状但海外实验室检查和临床检查排除当前传染性 TB 疾病的人员(B1 类)、患有潜伏性 TB 感染(LTBI)的人员(B2 类)和已知患有结核病的人的密切接触者(B3 类)。海外检查期间还可能提供自愿公共卫生干预措施。对于具有 B 类 TB 的人,建议在抵达美国后进行后续 TB 检查。
本报告总结了 2014-2019 年期间抵达美国的难民、移民和符合条件的其他人通过电子疾病通知(EDN)系统向 CDC 报告的健康信息。符合条件的其他人是指虽然不属于难民(例如,某些假释人员、特殊移民签证持有者和后续入境庇护申请人),但有资格享受与难民相同的服务和福利。
EDN 系统既有监测组件,也有方案组件。监测组件是一个集中式数据库,它从具有 A 类或 B 类条件的移民和所有难民和符合条件的其他人的海外体检中收集 1)与健康相关的数据,以及 2)从抵达后 TB 检查中收集与 TB 相关的数据。方案组件是一个报告系统,它向新抵达人员报告打算居住的州和地方卫生机构发送抵达通知,并向州和地方卫生机构和其他授权用户提供海外检查的医疗数据。
在 2014-2019 年期间,大约有 350 万人从国外移居美国,其中包括 320 万移民、31.3 万难民和 9.59 万符合条件的其他人。在这些人中,海外检查发现 139683 人(每 10 万人中有 3903 人)患有 B 类 TB、54 人患有原发性或二期梅毒(每 10 万人中有 30 人)、761 人患有潜伏性梅毒(每 10 万人中有 415 人),并且在 2016 年增加了淋病的实验室检测后,总共发现 131 人患有淋病(每 10 万人中有 374 人)。难民还获得了额外的自愿干预措施,包括疫苗接种和寄生虫的推定治疗。到 2019 年,麻疹疫苗的第一剂和第二剂覆盖率分别为 96%和 80%。在推荐采用推定治疗的难民人群中,根据具体方案,高达 96%的难民接受了治疗。对于海外检查发现的 139683 名患有 B 类 TB 的人,EDN 将抵达通知和海外医疗数据发送给适当的州或地方卫生机构,以促进抵达后的 TB 检查。在海外检查发现的 6586 名患有 B0TB 或 94533 名患有 B1TB 的 10119 人中,共有 67432 人(67%)向 EDN 报告了完整的抵达后检查。在海外检查发现的 35814 名 2-14 岁儿童中,有 20758 人(每 10 万人中有 58%)向 EDN 报告了完整的抵达后检查。(成年人在海外体检中通常不接受针对结核分枝杆菌免疫反应的检测。)在向 EDN 报告完整抵达后检查的人中,在抵达后的第一年中,患有培养阳性 TB 病的人数为 464 人(每 10 万人中有 688 例),患有 B0 或 B1TB 的人数为 11 人(每 10 万人中有 53 例),患有 B2TB 的儿童人数为 11 人。
在 2014-2019 年期间,海外体检系统防止了 6586 例传染性 TB、815 例梅毒和 131 例淋病的输入。当检查用于提供公共卫生干预措施时,大多数难民(高达 96%)接受了干预措施。对于已经完成的 88190 人进行了后续随访检查,发现了 475 例培养阳性的 TB 病,这是进一步限制美国 TB 病传播的重要机会,可以通过发现和为 LTBI 提供预防性护理或为患有该病的人提供治疗来实现。
联邦、州和地方卫生部门和机构应继续使用 EDN 数据监测、评估和改进针对即将赴美或最近抵达的移民、难民和符合条件的其他人的相关健康计划和政策。还应考虑提供额外的公共卫生干预措施(例如 LTBI 的治疗)。最后,对于患有 B 类 TB 的人,应采取措施,发现并消除完成抵达后检查的障碍,以降低 TB 病和社区传播的风险,同时采取措施鼓励报告完成的检查,以便更好地进行数据驱动的决策。